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Diabetes is the leading cause of CKD in the developed world. C-terminal fragment of agrin
(CAF) is a novel kidney function and injury biomarker. We investigated whether serum CAF
predicts progression of kidney disease in type 2 diabetics.
Methods
Serum CAF levels were measured in 71 elderly patients with diabetic nephropathy using a
newly developed commercial ELISA kit (Neurotune1). Estimated glomerular filtration rate
(eGFR) and proteinuria in spot urine were assessed at baseline and after 12 months follow
up. The presence of end stage renal disease (ESRD) was evaluated after 24 months follow-
up. Correlation and logistic regression analyses were carried out to explore the associations
of serum CAF levels with GFR, proteinuria, GFR loss and incident ESRD. Renal handling of
CAF was tested in neurotrypsin-deficient mice injected with recombinant CAF.
Results
We found a strong association of serum CAF levels with eGFR and a direct association with
proteinuria both at baseline (r = 0.698, p<0.001 and r = 0. 287, p = 0.02) as well as after 12
months follow-up (r = 0.677, p<0.001 and r = 0.449, p<0.001), respectively. Furthermore, in
multivariate analysis, serumCAF levels predicted eGFR decline at 12 months follow-up after
adjusting for known risk factors (eGFR, baseline proteinuria) [OR (95%CI) = 4.2 (1.2–14.5), p =
0.024]. In mice, injected CAF was detected in endocytic vesicles of the proximal tubule.
Conclusion
Serum CAF levels reflect renal function and are highly associated with eGFR and protein-
uria at several time points. Serum CAF was able to predict subsequent loss of renal function
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irrespective of baseline proteinuria in diabetic nephropathy. CAF is likely removed from cir-
culation by glomerular filtration and subsequent endocytosis in the proximal tubule. These
findings may open new possibilities for clinical trial design, since serum CAF levels may be
used as a selection tool to monitor kidney function in high-risk patients with diabetic
nephropathy.
Introduction
Chronic kidney disease (CKD) represents a global public health problem affecting more than 1
in 10 adults worldwide [1]. Diabetes is the leading cause of CKD in the developed world and
people with both diabetes and chronic kidney disease have a greatly increased risk of all-cause
mortality, cardiovascular mortality, and end-stage renal disease (ESRD) [2]. Although several
factors have been identified to predict risk of developing progressive nephropathy in diabetic
patient populations, none sufficiently predict the risk for individual patients [3].
Currently the simultaneous evaluation of albuminuria and glomerular filtration rate (GFR)
is recommended by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for
the prediction of progression in diabetic nephropathy [4]. A growing body of evidence chal-
lenges the traditional conceptual model of the course of diabetic nephropathy [5,6], since it can
present with a rapid decline of renal function and no overt albuminuria or progressive protein-
uria [7–10]. Based upon these clinical observations, more reliable biomarkers are urgently
needed in the clinic to predict renal outcome in patients with early stages of CKD in diabetic
nephropathy [11].
Agrin is the major heparin sulfate proteoglycan in the glomerular basement membrane and
a ubiquitous component of the extracellular matrix [12,13]. Neurotrypsin, a serine protease,
cleaves agrin at two distinct molecular sites generating a 110 kDa fragment (CAF110) at the
alpha site, whereas cleavage at the beta site produces the 22 kDa C-terminal fragment (CAF22)
[14]. In human urine, CAF22 can be detected, suggesting renal clearance for this small frag-
ment [15,16]. Furthermore, serum CAF22 (sCAF) as kidney function biomarker has only
recently been explored in septic patients and in renal transplant recipients [17,18]. Both studies
indicate that the sCAF concentration is associated and comparable to established parameters
of renal function such as creatinine and cystatin C.
However, to date, there are no clinical studies, which have investigated whether sCAF could
serve as biomarker in clinical practice for diabetic nephropathy and no animal studies address-
ing the renal handling of sCAF. We hypothesize that rising sCAF levels may reflect progression
of kidney damage and dysfunction. In this prospective study in a cohort of patients with dia-
betic nephropathy, we aimed to: 1) explore and validate the cross-sectional associations
between sCAF and the currently used clinical markers of kidney damage and dysfunction; esti-
mated glomerular filtration rate (eGFR) and proteinuria (protein to creatinine ratio [PCR]) 2)
examine the independent predictive performance of sCAF for renal function decline and ESRD
and 3) study the renal handling of CAF in neurotrypsin deficient mice lacking endogenous
CAF22 production.
Methods
Study design and patient cohort
The present study was designed as a prospective observational cohort study. Study subjects were
recruited from the outpatient clinic of Department of Nephrology, University Hospital of Alex-
androupoli, Greece. Patients were recruited if they fulfilled the following inclusion criteria; (i) age
CAF in Diabetic Nephropathy
PLOS ONE | DOI:10.1371/journal.pone.0143524 December 2, 2015 2 / 12
Competing Interests: Dr. Stefan Hettwer is
employed by Neurotune AG. The remaining authors
of this manuscript have no conflicts of interest to
disclose as described by the journal. The authors
confirm that this commercial affiliation does not alter
the authors' adherence to all PLOS ONE policies on
sharing data and materials as detailed online in the
guide for authors (http://www.PLOSone.org/static/
editorial.action#competing).
> 18 years, (ii) ability to provide written, informed consent (iii) type 2 diabetes, defined as the
use of oral glucose-lowering treatment, a fasting plasma glucose>7.0 mmol/l (126 mg/dl) or
non-fasting plasma glucose>11.1 mmol/l (>200 mg/dl). The presence of diabetic nephropathy
was defined by microalbuminuria [albumin to creatinine ratio 3–30 mg/mmol (30–300mg/g)] or
persistent albuminuria [(albumin: creatinine ratio>30 mg/mmol (>300mg/g)] in three consecu-
tive measurements in sterile spot urine sample during a 6-month period, presence of diabetic ret-
inopathy, and no clinical or laboratory evidence of kidney or urinary tract disease [19]. Subjects
were considered to have diabetic retinopathy if they showed nonproliferative or proliferative
stages in fundoscopy through dilated pupils or had a history of retinal laser surgery (photocoagu-
lation) for diabetic retinopathy.
The main exclusion criteria were clinical or laboratory evidence of non-diabetic nephropa-
thy such as active malignancy, infection or autoimmune disease. The study was approved by
the Ethics Committee of the Scientific Council of the University Hospital of Alexandroupoli,
was in accordance with Helsinki Declaration of Human Rights and all subjects gave written
informed consent.
The diagnosis and staging of CKD was assessed based on the Clinical Practice Guidelines
from the National Kidney Foundation–Kidney Disease Outcomes Quality Initiative [20]. GFR
was estimated (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equation
(CKD-EPI), which is more accurate and less biased than the MDRD Study equation, especially
in patients with higher GFR, resulting in reduced misclassification of CKD [21]. The onset of
ESRD was defined as the date of first dialysis or transplantation.
Biochemical analysis
After an overnight fasting of 8 h blood samples were drawn from a peripheral vein of the
patients into vacutainer tubes without anticoagulant in order to obtain serum. Samples for fast-
ing blood glucose levels, potassium, sodium, calcium, phosphate, protein, albumin, urea, creati-
nine and HbA1c were measured according to routine laboratory methods. Proteinuria was
determined in spot urine by an automated biochemistry analyzer (Clinical Chemistry System
ADVIA 2400, Siemens). Blood samples were immediately centrifuged at 4,000 rpm for 10 min
at ambient temperature, and the extracted serum was aliquoted and stored at 253 K (-20°C)
until use.
C-terminal agrin fragments (CAF)
CAF levels were measured using the NTtotalCAF ELISA kit from Neurotune AG (www.
neurotune.com). This assay detects both the large C-terminal agrin fragment CAF110 gener-
ated by alpha cleavage and the small C-terminal agrin fragment generated by beta cleavage
(CAF22). The molecular ratio of both fragments is 1:5 (CAF110 vs CAF22). In brief, serum
samples were diluted two-fold with sample incubation buffer and heated to 329 K (56°C) for
30 minutes. Samples were diluted 20 fold with dilution buffer. 100 μL of diluted sample was
added to an ELISA plate pre-coated with a monoclonal catcher antibody raised against CAF.
The plate was then incubated for 16 hours at room temperature. After rinsing 3 times with
washing buffer, the monoclonal detector antibody was added for 30 minutes at room tempera-
ture. The plate was then washed as previously described [6]. Streptavidin- conjugated HRP was
then added for 30 minutes at room temperature. After washing, TMB substrate was added and
developed for 30 minutes. The reaction was then stopped with an acidic solution and the result-
ing absorbance was measured on an ELISA plate reader at 450 nm. The results were quantified
using the calibration curve prepared independently on each individual plate. The lower
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detection limit was 40 pmol/L. Independent analysis revealed a mixed intra- and inter-assay %
CV< 13% for serum samples.
Statistical analysis
Variables were tested for normality using the Kolmogorov-Smirnov test. Comparisons between
categorical variables were performed by the chi- square test or the Fisher’s exact test when
appropriate. Differences in continuous variables between two groups were assessed using the
Student’s t-test, the Mann-Whitney’s U-test or one-way ANOVA when appropriate. Pearson
and Spearman correlation coefficients were calculated as appropriate between CAF or logarith-
mic transformed CAF (to achieve normal distribution), creatinine, GFR, proteinuria, age, BMI,
HbA1c and duration of T2DM at baseline and at 12 months follow-up. Correlation analysis of
decline of renal function (ΔGFR) and progression to ESRD with various risk factors was also
conducted to determine possible outcome predictors.
Multiple logistic regression analysis was carried out to further explore the predictive role of
serum CAF levels with GFR decline. The variables entered in the models were known risk fac-
tors associated with progression of kidney disease. For both outcomes a basic and an advanced
model were used with the following variables: 1) Basic model A: CAF, baseline GFR and base-
line proteinuria, 2) Advanced model B: CAF, baseline GFR, baseline proteinuria, renin-angio-
tensin-aldosterone system blockade, age and BMI; and 3) Advanced C: Serum creatinine,
baseline GFR, baseline proteinuria, renin-angiotensin-aldosterone system blockade, age and
BMI. Variables retained in all final models were chosen according to clinical significance. The
dataset variables can be found in the supporting Information dataset (S1 Table). A two-sided
p value< 0.05 was considered significant. The IBM SPSS Statistics 20.0 statistical software
package (SPSS Insc, Chicago, Illinois, USA) was used for all calculations.
Animal experiments
Experiments were performed in 8–10 weeks old male neurotrypsin knockout mice (NT KO).
The generation and genotyping of neurotrypsin KO mice has been previously described [22].
All animal experiments were conducted according to Swiss laws for the welfare of animals and
were approved by the local Zurich Veterinary Authority (Kantonales Veterinäramt Zürich).
The animals had free access to food and tap water.
Mice were pretreated 60 min before experiments with an injection of leupeptin (5 mg/
mouse, Sigma Aldrich, Buchs, Switzerland), an inhibitor of lysosomal degradation. Wildtype
and neurotrypsin KO mice were anesthetized by i.p. injection of xylazin and ketamin and were
injected with 100 ml of a mixture containing recombinant hCAF22 (100 ng/mouse, produced
by Neurotune) dissolved in 0.9% NaCl and FITC-labeled sinistrin (100 ng/ mouse). FITC-sinis-
trin is cleared from circulation exclusively by glomerular filtration and served as control for
successful injection. Before injection of hCAF, the urinary bladder was completely emptied
through a small abdominal incision to allow collection of urine produced during the experi-
mental period. Mice received also a bolus i.p. of 0.5 ml of 25 mMNaHCO3/150 mMNaCl to
prevent dehydration and to promote diuresis. Mice were kept warm at 37°C by placing animals
on a heating tablet for the rest of the experiment. Twenty or 60 minutes after hCFA injections,
mice perfused with PBS and PLP (see below) through the heart to obtain fixed kidneys for later
immunohistochemistry and localization of recombinant hCAF.
Immunohistochemistry
Mice were anesthetized with ketamine/xylazine (i.p.) and systemically perfused through
the left ventricle with phosphate-buffered saline (PBS) to remove blood followed by
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paraformaldehyde-lysine-periodate (PLP) fixative (50 ml/mouse) [23]. Kidneys were
removed and fixed overnight at 4°C by immersion in PLP. Kidneys were washed 3 times with
PBS and 5 μm cryosections were cut after cryoprotection with 2.3 M sucrose in PBS for at
least 12 h. Immunostaining was carried out as described previously [24]. Briefly, sections
were shortly incubated in microwave with Tris-HC [pH 10], following 1% (wt/vol) SDS for
5 min for retrieval of antigenic sites, washed 3 times with PBS and incubated with PBS con-
taining 1% bovine serum albumin for 15 min prior to the primary antibody. The primary
antibodies were mouse monoclonal anti cleaved Agrin Abs (CAF; 14B7B8; 1:1000) and
(CAF; 12A11D11; 1:1000) (provided by Neurotune diluted in PBS and applied overnight at
4°C. Sections were then washed twice for 5 min with high NaCl PBS (PBS + 18 g NaCl/l),
once with PBS, and incubated with dilutions of the secondary antibodies (donkey anti-rabbit
594 (1:500), donkey anti-mouse 488 (1:200), donkey anti-mouse Alexa 594 (1:500), donkey
anti-rabbit Alexa 488 (1:500) (Molecular Probes, Oregon, USA) and from DAPI (1 mg/ml)
(1:500) for 1 h at room temperature. Sections were again washed twice with high NaCl PBS
and once with PBS before mounting with VectaMount (Vector Laboratories, Burlingame,
CA). Sections were viewed with a Zeiss LSM 410 confocal microscope or a Leica DFC490
charged-coupled device camera attached to a Leica DM 6000 fluorescence microscope (Leica,
Wetzlar, Germany). Images were processed (overlays) using Adobe Photoshop.
Results
Study population
A total of 71 consecutive patients with long standing (>10 years) diabetic nephropathy, were
recruited from January 2010 to December 2014. A full medical history and physical examina-
tion was performed by a trained physician at baseline (time-point 0; T0) and after 12 months
(time-point 1; T1). All patients were of Caucasian origin. Demographic, clinical and laboratory
data of all enrolled patients at T0 and T1 as well as of groups of progressors (loss of
GFR> 1ml/min/1.73m2) and non progressors (stable GFR) are given in Table 1.
There was no significant difference in age, BMI and duration of T2DM across the categories
of patients with and without GFR decline. Urea and phosphate concentrations were signifi-
cantly different across groups and as expected, increased in the group of patients with
decreased GFR (p = 0.004, 0.03 respectively). There were significantly more males than females
among GFR decliners compared with those with stable or increased GFR (62,5% vs 35,4%,
p = 0.024). sCAF levels showed a trend towards higher values in those with deterioration of
renal function (p = 0.09).
Correlation analysis
Correlation matrix analysis showed that values of creatinine and eGFR at both time-point 0
and time-point 1 were significantly associated with sCAF levels (p<0.001) (Fig 1). sCAF con-
centration was also correlated with proteinuria at baseline and at T1 (p = 0.02 and p<0.001,
respectively) (Fig 1). Furthermore, sCAF levels were strongly correlated with progression to
ESRD (r = 0.314, p = 0.008) (Fig 1). At 24 months follow-up (time point 2; T2) 6 of the 71
patients progressed to ESRD (8.5%). Baseline sCAF levels were significantly elevated in those
who reached ESRD compared to the group of patients that did not (p = 0.009). sCAF also
showed a significant association with the rapid increase of proteinuria (>500 mg/day) at T1
(r = 0.340, p = 0.004) (Fig 1). The baseline sCAF level was higher in those who presented a
rapid increase of proteinuria than in patients with stable, decreased or mild increase (<500
mg/day) of proteinuria (p = 0.005). A significant positive association was observed between
rapid increase of proteinuria and progression to ESRD (x2, p = 0.005).
CAF in Diabetic Nephropathy
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Logistic regression analysis
Logistic regression models of the association of renal outcomes (defined as GFR decline>
1ml/min1.73m2) with baseline sCAF levels and other clinically significant regressors, assessed
by 2 complementary models: Basic model A (CAF, baseline GFR and baseline proteinuria) and
advanced model B (CAF, baseline GFR, RAAS-Blockade, baseline proteinuria, age, BMI) are
shown in Table 2. CAF was the only variable which was significantly associated with GFR loss
( 1 ml/min/1.73m2) in both model A [OR (95%CI) = 4.2 (1.2–14.5), p = 0.024] and model B
[OR (CI) 4.15 (1.14–15.07), p = 0.031]. Performing a logistic regression analysis based on the
advanced model including serum creatinin (model C) resulted in a non-significantly associated
OR concerning GFR loss compared to CAF (p = 0.079).
Table 1. Anthropometric, clinical and biochemical characteristics of patients with TD2M and CKDwith stable (or increased) and with decreased
GFR at one year follow-up.
All patients (N = 71) Stable GFR (N = 31) Decreased GFR (N = 40) P-valuea
Age (years) 70.9 (8.8) 71.8 (6.4) 70.2 (10.3) 0.79
Gender (M/F) 36/35 11/20 25/15 0.024*
BMI (kg/m2) 32.4 (5.9) 33.0 (5.9) 31.9 (6.0) 0.49
Duration of T2DM (years) 17.4 (9.7) 16.5 (7.6) 18.1 (11.2) 0.83
RAAS blockade (%) 49 (69) 25 (80.6) 24 (60) 0.06
Urea (mg/dl) 13.1 (6.76) 10.5 (3.98) 15.1 (7.77) 0.004*
Potassium (mEq/L) 4.8 (0.5) 4.7 (0.3) 4.9 (0.6) 0.34
Sodium (mEq/L) 138.3 (3.0) 138.2 (3.0) 138.4 (3.0) 0.71
Calcium (mmol/L) 2.35 (0.15) 2.38 (0.13) 2.33 (0.18) 0.35
Phosphate (mmol/L) 1.23 (0.26) 1.16 (0.19) 1.29 (0.29) 0.03*
Protein (g/L) 73 (6) 74 (07) 72 (6) 0.34
Albumin (g/L) 43 (4) 44 (3) 42 (4) 0.06
HbA1c (%) 8.6 (9.3) 7.5 (1.3) 9.5 (12.3) 0.88
Crea T0 (mg/dl) 123.8 (53) 114.9 (35.4) 132.6 (61.9) 0.19
Crea T1 (mg/dl) 123.8 (79.6) 106.1 (35.4) 150.3 (79.6) <0.001*
eGFR T0 (ml/min/1.73 m2) 43 (27) 44 (23) 40.5 (30.5) 0.62
eGFR T1 (ml/min/1.73 m2) 43 (27) 54 (24) 34 (23) <0.001*
ΔGFR T0-T1 (ml/min/1.73 m2) -2.0 (11) 5.0 (8) -6.0 (8) <0.001*
PU T0 (mg/24h) 270 (600) 245 (430) 370 (705) 0.28
PU T1 (mg/24h) 300 (770) 240 (490) 465 (985) 0.059
ΔPU T0-T1 (mg/24h) 10 (270) 0 (200) 45 (390) 0.19
ESRD (%) 6 (8.5) 0 (0) 6 (15) 0.024*
Total CAF (pmol/L) 1091.4 (890.2) 993.4 (737.8) 1145.9 (1571.1) 0.09
Continuous variables are presented as mean (S.D.) or median (interquartile range, IQR).
a P values of Mann-Whitney U or one-way ANOVA test for differences of variables among patients with stable or decreased eGFR at one year follow-up.
* Statistical signiﬁcance at the 0.05 level (two-tailed).
BMI, body mass index; HbA1c, glycosylated hemoglobin A1c; RAAS blockade, use of medicines affecting renin–angiotensin system; Crea T0, serum
creatinine levels at timepoint 0 (baseline); Crea T1, serum creatinine levels at timepoint 1 (12 months); eGFR T0, estimated GFR assessed by the
CKD-EPI formula at timepoint 0 (baseline); eGFR T1, estimated GFR assessed by the CKD-EPI formula at timepoint 1 (12 months); PU T0, Proteinuria
assessed by protein to creatinine ratio at timepoint 0 (baseline); PU T1, Proteinuria assessed by protein to creatinine ratio at timepoint 1 (12 months);
ΔGFR T0-T1, Algebric difference between eGFR at timepoint 1 and eGFR at timepoint 0; ΔPU T0-T1, Algebric difference between Proteinuria at timepoint
1 (12 months) and Proteinuria at timepoint 0 (baseline); ESRD, progression to end stage renal disease; Total-CAF, serum levels of C-terminal agrin
fragment; Decreased GFR, patients with loss of eGFR  1 ml/min/1.73m2 during the 12 month follow-up.
doi:10.1371/journal.pone.0143524.t001
CAF in Diabetic Nephropathy
PLOS ONE | DOI:10.1371/journal.pone.0143524 December 2, 2015 6 / 12
Animal experiments
In order to test for the role of the kidney in determining serum CAF levels, we injected recom-
binant human CAF22 into neurotrypsin KO mice. These mice lack endogenous CAF22 due to
the absence of the specific protease required for the cleavage of agrin [22]. In kidneys from NT
KOmice injected with saline, no recombinant hCAF22 could be observed providing evidence
for the specificity of the antibody. However, full length agrin was detected in the glomerulum
and in the basement membrane of all tubules (Fig 2A). Twenty and sixty minutes after
hCFA22 injections, hCAF22 accumulated in subapical vesicles along the proximal tubule con-
sistent with the reabsorption of hCFA22 from urine via apical endocytosis (Fig 2B–2F).
Discussion
The major findings in this prospective study of predominantly elderly patients with long-term
diabetic nephropathy are that sCAF levels are strongly associated with eGFR and proteinuria.
Of note these associations were preserved and evident in subsequent measurements for both
parameters at T1. Higher baseline sCAF levels were significantly correlated with progression to
ESRD and notably elevated in subjects with an overt increase of proteinuria at T1. Further-
more, sCAF levels predicted loss of renal function, as mirrored by eGFR decline at T1 even
Fig 1. Correlation analysis of CAF levels with variables of laboratory and clinical significance and scatterplots of CAF with GFR and proteinuria.
Values represent Spearman’s correlation coefficients. a Correlation is significant at the 0.05 level (2-tailed). HbA1c, glycosylated hemoglobin A1c; T0, Time
point 0 (Baseline); T1, Time point 2 (12 months); Δ-Proteinuria T0-T1, Increase of proteinuria (500mg/day) during the first year of follow-up.
doi:10.1371/journal.pone.0143524.g001
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after adjusting for multiple well established risk factors, and in particular, for baseline GFR and
proteinuria.
Our results are consistent with previous studies that have reported associations between
sCAF levels and renal function. Steubl et al. showed that sCAF was highly correlated with kid-
ney function in a renal transplant cohort [18]. Additionally, Drey and colleagues demonstrated
that sCAF levels are strongly associated and comparable to established renal function parame-
ters (creatinine and cystatin C) in critical ill patients [17]. In the present study, serum levels of
CAF at baseline were significantly higher in diabetics, which progressed to ESRD. Importantly,
the association between sCAF levels and the different aspects of kidney dysfunction were also
evident irrespective of proteinuria. Although sCAF reflect renal function and is highly associ-
ated with eGFR and proteinuria at several time points, it predicted loss of renal function also in
the absence of proteinuria in diabetic nephropathy. sCAF seems to overcome a significant
prognostic restriction of proteinuria in a subset of patients with rapid decline of renal function
and no progressive proteinuria, a finding that to our knowledge has not been reported before.
Our animal experiments are consistent with the hypothesis that CAF22 is cleared from the
circulation by glomerular filtration. Injected human recombinant hCAF22 accumulated in sub-
apical vesicles along the proximal tubule. These vesicles likely represent endocytic vesicles con-
taining low molecular weight proteins that escaped the glomerular filtration barrier. CAF22
has only 22 kDa size and is expected to be filtered to a large extent similar to other proteins of
this size [25]. The subapical localization of vesicles containing hCAF22 strongly suggests that
hCAF22 is taken up from urine by endocytosis, possibly receptor-mediated endocytosis. It is
unlikely that hCAF22 is secreted into urine by proximal tubules in quantitatively relevant
Table 2. Association of GFR-decline with serumCAF and additional clinical regressors.
GFR decline at 1 year  1 ml/min/1.73m2
ORa CIb P-value
Model A logCAF 4.18 1.2–14.5 0.024*
eGFR T0 1.03 0.99–1.08 0.102
PU T0 1.0002 0.99–1.0006 0.299
Model B logCAF 4.15 1.14–15.07 0.031*
eGFR T0 1.03 0.99–1.08 0.109
RAAS-Block 0.3 0.09–1.06 0.064
PU T0 1.0002 0.99–1.0006 0.321
Age 1.001 0.93–1.07 0.964
BMI 0.97 0.89–1.07 0.438
Model C SCreat T0 6.3 0.8–50.29 0.079
eGFR T0 1.05 0.98–1.12 0.104
RAAS-Block 0.4 0.12–1.5 0.202
PU T0 1.0002 0.99–1.0006 0.348
Age 1.020 0.95–1.009 0.554
BMI 0.99 0.90–1.08 0.321
a OR, odds ratio
b CI, 95% conﬁdence interval
* Signiﬁcance levels at 0.05
BMI, body mass index; eGFR T0, estimated GFR assessed by the CKD-EPI formula at baseline; PU T0, Proteinuria assessed by protein to creatinine
ratio at baseline; logCAF, serum CAF levels (log-transformed). GFR, estimated glomerular ﬁltration rate; SCreat, Serum creatinine; renin-angiotensin-
aldosterone system blockade (RAAS-Block).
doi:10.1371/journal.pone.0143524.t002
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amounts since we never detected hCAF22 positive vesicles close to the basolateral membrane.
Reabsorption of hCAF22 along with other low molecular weight proteins will determine its uri-
nary excretion. Thus, reduced glomerular filtration in kidney disease would increase serum
CAF22 levels whereas a selective reduction in proximal tubular reabsorption may increase uri-
nary CAF22 levels. While the exact mechanism of CAF production and trafficking in the kid-
ney is currently under investigation, our findings further support the notion that CAF may
reflect both structural (proteinuria) and functional (glomerular filtration rate) alterations.
CKD has a major public impact worldwide, with a global prevalence of 10% and diabetic
nephropathy is the primary reason of CKD [1,26,27]. sCAF may represent a promising bio-
marker of kidney damage and progression to ESRD in diabetic nephropathy. However, more
studies with sufficient follow up are needed to evaluate the clinical value of sCAF measure-
ments for: 1) the detection of kidney damage, 2) the prediction of GFR decline and 3) the
development of ESRD. The correlation between sCAF levels and the progression of kidney dys-
function in other cohorts [28] as well as in the present study indicates that sCAF measurements
may be of clinical importance. This finding may open new possibilities for clinical trial design,
since sCAF levels could be used as a selection tool for high-risk patients (individuals with CKD
and in particular with diabetic nephropathy and no overt proteinuria at baseline) and for mon-
itoring treatment effects in diabetic nephropathy.
Limitations of the present study include the single center design, the short-term follow-up
and unknown cross-relevance to other age and ethnic groups. While a multitude of relevant
variables were adjusted in our multivariate analyses, as with all observational studies, it is possi-
ble that unmeasured confounders may have influenced our estimates and results. No conclu-
sions regarding causality should be drawn from our prospective observational data. However,
the strong associations with eGFR and proteinuria in diabetics are of interest because sCAF has
been shown to be a prognostic marker of kidney dysfunction in other cohorts including
patients with CKD and in critically ill patients with acute kidney injury [17,18].
Our findings suggest that sCAF, a novel kidney function and injury biomarker, is associated
with subsequent renal function loss irrespective of proteinuria at baseline. The association we
observed was strong and was not altered by adjusting for several risk factors. sCAF levels pro-
vide important information on the long-term outcome of patients with diabetic nephropathy,
which exceed a simple reflection of glomerular filtration rate and proteinuria. sCAF measure-
ments may have a substantial impact on clinical trial design as a selection tool since it holds the
potential to identify individuals with the higher progression risk for diabetic nephropathy. Fur-
ther studies are needed in order to replicate our results and to confirm sCAF as a monitoring
tool for rapid disease progression in diabetic kidney disease.
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S1 Table. Supporting Information dataset. Dataset with available variables as excel file and
codebook.
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Fig 2. Accumulation of recombinant hCAF22 in mouse proximal tubule.Mice were injected with saline or hCAF22 and all sections stained in parallel
with the antibodies as indicated. A. Localization of full length agrin (red) and hCAF22 (green) in NT KO kidney injected with saline. B. Localization of full
length agrin (red) and hCAF22 (green) in NT KOmouse kidney 20 min after hCAF22 injections. C. Localizations of hCFA22 (green) and actin (red) in NT KO
mouse kidney 20 min after hCAF22 injections. D. Localization of full length agrin (red) and hCAF22 (green) in NT KOmouse kidney 60 min after hCAF22
injections. E-F. Localizations of hCFA22 (green) and actin (red) in NT KOmouse kidney 60 min after hCAF22 injections. A- E Original magnifications
between 400–630 x, for F original magnification 1000 x.
doi:10.1371/journal.pone.0143524.g002
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